Alzheimer's DiseaseNCT05837819
Methodology Issues in a Tailored Light Treatment for Persons With Dementia - Aim 2
A study testing Active Lighting Intervention in people with Alzheimer's Disease and Sleep Disturbance, run by Icahn School of Medicine at Mount Sinai at 2 sites in United States.
Trial summary
Aim 2 will investigate the effect of 3 different light exposure lengths on sleep, mood and agitation in persons with Alzheimer's disease. Participants will be randomly assigned to one of three conditions of light exposure: 1) 2-h morning light exposure; 2) 4-h morning light exposure; and 3) all day light exposure. Read more about this study
- Who is it for?
- Ages 65 years and older
- Conditions the study is for
- Alzheimer's Disease, Sleep Disturbance
- What is being tested?
- Active Lighting Intervention
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 135 participants
- Where
- 2 sitesUnited States
- Study dates
- 14 Feb 2023to 31 Jul 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 65 years and older
- All sexes
- No healthy volunteers
- Older adult
Who may be able to join
- Diagnosis of Alzheimer's disease or related dementia with a Montreal Cognitive Assessment score <25
- Sleep disturbance with a Pittsburgh Sleep Quality Index score ≥5
Who cannot join
- Extensive brain vascular disease, traumatic brain injury, multiple sclerosis, Parkinson's Disease
- Obstructing cataracts
- Severe macular degeneration
- Use of sleep medication
- Use of oral melatonin
- untreated moderate to severe sleep apnea
- Severe restless leg syndrome
- Blindness
Trial locations and contacts
2 sites in 1 country.
United States2 sites
Icahn School of Medicine at Mount Sinai
Albany, New York, 12204
Icahn School of Medicine at Mount Sinai
New York, New York, 10029
About this study
Aim 2 will investigate the effect of 3 different light exposure lengths on sleep, mood and agitation in persons with Alzheimer's disease. Participants will be randomly assigned to one of three conditions of light exposure: 1) 2-h morning light exposure; 2) 4-h morning light exposure; and 3) all day light exposure.
- Conditions
- Alzheimer's Disease, Sleep Disturbance
- Being tested
- Active Lighting Intervention, Control Lighting Intervention
- Medical subject headings
- Alzheimer Disease, Parasomnias
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Active Lighting InterventionDevice
Lighting intervention using high light levels designed to effect the circadian system
Control Lighting InterventionDevice
Lighting intervention using low light levels designed to not effect the circadian system
| Study group | Role | What they receive |
|---|---|---|
| Active Lighting Intervention | Active comparator | Lighting intervention designed to effect the circadian system then will receive the control lighting intervention. Receives: Device: Active Lighting Intervention; Device: Control Lighting Intervention |
| Control Lighting Intervention | Placebo comparator | Lighting intervention using low light levels designed to not effect the circadian system Receives: Device: Control Lighting Intervention |
What is being measured
The primary outcome is the main question the study is designed to answer.
Sleep Disturbance using the Pittsburgh Sleep Quality Index
The PSQI is used to measure sleep quality and is composed of 19 items that generate 7 component scores (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction). Each subscale is scored 0 to 3. The sum of the 7 component scores yields a single global score with a range of 0 to 21. A higher score indicates higher sleep disturbance
Measured: up to week 14
Secondary outcomes (1)
Sleep efficiency using actigraphy
Actigraphs will be worn continuously for 7 days during each assessment week. Changes in sleep efficiency will be measured using the actigraphy software. Sleep efficiency is a calculated as a ratio of the time spent in bed and the time spent sleeping.
Measured: up to week 14
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted1 May 2023
- Study start14 Feb 2023
- Primary completion31 Jul 2025
- Study completion31 Jul 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Alzheimer's DiseaseStudies of the same condition, open and under way.
- More trials run by Icahn School of Medicine at Mount SinaiThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind
- Who is masked
- Participant
- Enrolment
- 135 participants (actual)
Sponsor and investigators
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Mariana Figueiro, Icahn School of Medicine at Mount Sinai
- Investigators
- Mariana Figueiro, PhD, Principal investigator, Icahn School of Medicine at Mount Sinai
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05837819
- Sponsor's protocol ID
- STUDY-20-01736 Aim 2
- Status last verified
- May 2026
- First submitted
- 20 Apr 2023
- Last updated
- 1 Jun 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No: Overall results will be shared, not individual data
Study at a glance
From the registry record, last updated by the sponsor on 1 Jun 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Methodology Issues in a Tailored Light Treatment for Persons With Dementia - Aim 2
- ClinicalTrials.gov ID
- NCT05837819
- Acronym / sponsor ID
- STUDY-20-01736 Aim 2
- Conditions
- Alzheimer's Disease, Sleep Disturbance
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 135 participants (actual)
- Lead sponsor
- Icahn School of Medicine at Mount SinaiUniversity, hospital or other
- Study start
- 14 Feb 2023 (actual)
- Primary completion
- 31 Jul 2025 (actual)
- Study completion
- 31 Jul 2025 (actual)
- First posted
- 1 May 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Aim 2 will investigate the effect of 3 different light exposure lengths on sleep, mood and agitation in persons with Alzheimer's disease. Participants will be randomly assigned to one of three conditions of light exposure: 1) 2-h morning light exposure; 2) 4-h morning light exposure; and 3) all day light exposure.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Single blind (participant)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Active Lighting Intervention | Active comparator | Device: Active Lighting Intervention, Device: Control Lighting InterventionLighting intervention designed to effect the circadian system then will receive the control lighting intervention. |
| Control Lighting Intervention | Placebo comparator | Device: Control Lighting InterventionLighting intervention using low light levels designed to not effect the circadian system |
Who may qualify
- Ages
- 65 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Older adult
Key inclusion criteria (2 listed)
- Diagnosis of Alzheimer's disease or related dementia with a Montreal Cognitive Assessment score <25
- Sleep disturbance with a Pittsburgh Sleep Quality Index score ≥5
Key exclusion criteria (8 listed)
- Extensive brain vascular disease, traumatic brain injury, multiple sclerosis, Parkinson's Disease
- Obstructing cataracts
- Severe macular degeneration
- Use of sleep medication
- Use of oral melatonin
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Active Lighting InterventionLighting intervention using high light levels designed to effect the circadian system | Device | Active Lighting Intervention |
| Control Lighting InterventionLighting intervention using low light levels designed to not effect the circadian system | Device | Active Lighting Intervention, Control Lighting Intervention |
Primary outcome
Sleep Disturbance using the Pittsburgh Sleep Quality Index
Time frame: up to week 14
The PSQI is used to measure sleep quality and is composed of 19 items that generate 7 component scores (subjective sleep quality, sleep latency, sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction). Each subscale is scored 0 to 3. The sum of the 7 component scores yields a single global score with a range of 0 to 21. A higher score indicates higher sleep disturbance
1 secondary outcome
Sleep efficiency using actigraphy
Time frame: up to week 14
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 1 Jun 2026.
- Individual participant dataSharing planned: No. Overall results will be shared, not individual data
Related trials for Alzheimer's Disease
RecruitingObservational study
PET Imaging in the Baltimore Longitudinal Study of Aging (BLSA)
Aging
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Alzheimer's Disease
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Assessing Treatment With High-phenolic EVOO Supplements for Neurovascular Activity
Mild Cognitive Impairment (MCI)
Active, not recruiting
Effectiveness of Strength-based Intervention for Elderly With Dementia Living in the Community
Dementia, Mild Cognitive Impairment
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Mariana Figueiro, PhD principal investigator
Icahn School of Medicine at Mount Sinai
2 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Active Lighting Intervention in people with Alzheimer's Disease and Sleep Disturbance, run by Icahn School of Medicine at Mount Sinai at 2 sites in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 8 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 1 Jun 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 2 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Sleep Disturbance using the Pittsburgh Sleep Quality Index (time frame: up to week 14). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jun 2026.